



# ODI Pharma

## Year-end Report

July 2021 – June 2022

25<sup>th</sup> Aug 2022

## ODI PHARMA YEAR-END REPORT

*In this year-end report, the following definitions apply, unless stated otherwise: The “Company” or “ODI Pharma” refers to ODI Pharma AB with org. number (Swedish corporate registration number) 559223-1392. Amount in brackets refers to the corresponding period in the previous year.*

*ODI Pharma AB was formed on the 23<sup>rd</sup> of October 2019. ODI Pharma AB is the Swedish holding company of ODI Pharma Schweiz AG and ODI Pharma Polska Sp. z o.o. The group was established on the 28<sup>th</sup> of June 2018 when ODI Pharma Schweiz AG acquired the shares in ODI Pharma Polska Sp. z o.o.*

### **Fourth quarter (2022-04-01 – 2022-06-30)**

The Group's net sales amounted to SEK 14,233 (0).

The Group's loss after financial items amounted to SEK -2,378,022 (-1,886,158).

Result per share amounted to SEK -0,16 (-0,12).\*

The solidity as of 2022-06-30 was 88,48% (96,55%).\*\*

### **Twelve months (2021-07-01 – 2022-06-30)**

The Group's net sales amounted to SEK 544,151 (0).

The Group's loss after financial items amounted to SEK -7,299,193 (-3,967,324).

Result per share amounted to SEK -0,48 (-0,26).\*

The solidity as of 2022-06-30 was 88,48% (96,55%).\*\*

*\* The Company's result per share: The result for the period divided by the number of shares at the end of the period. The total number of shares as of 30<sup>th</sup> of June 2022, amounted to 15,220,000 (15,220,000) shares. The result per share based on the average number of shares of 15,220,000 (15,220,000) amounts to SEK -0,48 (-0,26) for the twelve months 2021-07-01 to 2022-06-30.*

*\*\* Solidity: Equity divided by total capital.*

### **Highlights during the fiscal year**

#### *Fourth quarter (2022-04-01 – 2022-06-30)*

- No significant highlights during the period.

#### *Third quarter (2022-01-01 – 2022-03-31)*

- No significant highlights during the period.

#### *Second quarter (2021-10-01 – 2021-12-31)*

- November – ODI Pharma published its annual report for the fiscal year 2020/2021.
- December – ODI Pharma held its Annual General Meeting in the office of the Company. A summary of the resolutions can be found on the Company's website (<http://www.odipharma.com>).

#### *First quarter (2021-07-01 – 2021-09-30)*

- July – ODI Pharma announced that Niclas Kappelin acquired 20,000 shares in ODI Pharma and that he thereby exceeded the threshold of five percent.
- August – ODI Pharma approved the official launch of the exclusive CBD-infused skincare line kandol., which will be available online at [www.kandol.net](http://www.kandol.net) starting mid-September 2021.

- September – ODI Pharma announced that the official launch date of kandol. will be 1<sup>st</sup> of October 2021. The products will initially be available at [www.kandol.net](http://www.kandol.net) to customers within the EU.

#### Highlights after the end of the fiscal year

- No significant highlights after the end of the fiscal year.

## MARKET VIEW OF ODI PHARMA

ODI Pharma continues to share observations of trends in the cannabis industry for investors/potential investors.

During the last quarter, the majority of articles that we have followed have had a focus on the race for full recreational legalization in Germany and US (Who will be first?). Although we have discussed in previous reports the importance for the industry, we believe that both are significant and will eventually happen. However, Germany at the moment seems to have a bit of the upper hand and fewer barriers to pass the law with recent support from the Minister of Justice expressing support. We are very confident that this is a great step forward for the industry in Europe and we are following closely. Also, Switzerland legalizing medical cannabis offers opportunities.

What has also been happening in the background is continued studies of the benefits of Medical Cannabis for various ailments. The two recent studies have involved anxiety in youth and studies with Fibromyalgia. Both of which effect the society in a large scale and the medical applications if become accepted, will place medical cannabis in reach of a very large part of the population. Please follow the following research papers: ("Predictors of pain reduction among fibromyalgia patients using medical cannabis: A long-term prospective cohort trial," appears in Arthritis Care & Research. Additional information on cannabinoids and FM is available from NORML.), ("Cannabidiol for treatment-resistant anxiety disorders in young people: An open-label trial," appears in The Journal of Clinical Psychiatry.)

The above two studies are just a couple of the reasons that we have chosen our path at ODI and we see exponential opportunities to help people and we are positioning ourselves for this opportunity. There are continued research studies in many segments of the medical industry that we are continuing to process and add to points supporting our industry.

In Summary, legalization and acceptance is moving forward and some big hurdles have been achieved over the last quarter. We see very clearly that Europe is playing catchup to North America in the industry.

It is our hope that this market insight will help investors gain an understanding of how ODI Pharma surveys the landscape of the industry.

## COMMENTS BY CEO DEREK SIMMROSS



ODI Pharma has made several important steps on our journey to strengthen our presence in the European market for medicinal cannabis during the last fiscal year. We have also expanded our business this last year by creating a specialized CBD skin care line, launched under the brand kandol.

The launch of kandol. has been one of our highlights during the last year. We are very pleased with the acceptance and interest in our products and are certain that the presence of cannabinoids in cosmetics will continue to grow over the next years. I am confident that our products are based on a disrupting formula that has the possibility to show outstanding effects. Our products were nominated for a range of awards, amongst others for the Vogue Beauty Awards 2022. Moving into a new year, we will continue to spread awareness of kandol. and hope to see the continued promotion of our products in important channels for the cosmetics industry; offline and online, with a focus on Social Media. We have completed the first phase of our business model to set the infrastructure in place in Central Europe and Scandinavia.

We are continuously making progress with Project Poland – understandably, the most important aspect of our business, and we optimistically see results in the not-so-distant future. The importance

of this is well understood. – We are looking forward to being able to provide Polish patients with medicine of high quality at a competitive price. We are continuously looking at the existing supply chain in Poland and can clearly see that it does not meet the current demand. Therefore, we see great growth potential in the Polish market and are sure that we will play an important role in the solution for patients suffering from MS, Epilepsy and other illnesses that are clearly benefitting from medicinal cannabis.

In terms of other markets of interest, we are continuously monitoring the acceptance of medicinal cannabis throughout Europe and are preparing steps in several markets. We are highly confident in our Poland approach and over time many countries will benefit greatly from our products.

I want to thank our shareholders for your continued trust in ODI Pharma's journey. I am confident that we have made great progress during this last year and that we are well positioned to increase the brand knowledge of ODI Pharma and kandol. in the medical cannabis and cosmetics industry. We have an exciting year ahead of us!

**Derek Simmross**

CEO, ODI Pharma AB

## ABOUT ODI PHARMA

ODI Pharma, based on its European network, subsidiaries, and partners, is a producer and representative of finished pharmaceutical cannabis and cosmetics products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals. The main focus of ODI Pharma is on the medical cannabis products that are sold to clients and patients through ODI Pharma's relationships with pharmacies via wholesale distributors. According to the Company, cosmetics is a perfect complementary addition to its pharmaceutical focus, allowing ODI Pharma to benefit from synergies and mutual benefits.

On the 22<sup>nd</sup> of February 2021, ODI Pharma submitted the application to achieve a marketing authorization in Poland. This is the permit required to carry out medical cannabis operations and upcoming business activities in the Polish market. The process is going as expected and the Company hopes to be able to start operations in the not-so-distant future. ODI Pharma's Polish medical cannabis operations are carried out through its subsidiary on the Polish market, which handles the imports, distribution and supporting Swiss education for medical cannabis products. The Company has secured a relationship with one of the leading pharmaceutical wholesalers in Poland, NEUCA. Further, the Company has secured a valuable supply contract with a wholly owned subsidiary of the largest cannabis producer in the world. The supplier is a first-tier producer who operates at the highest standards.

ODI Pharma believes that European clients require a wide variety of medical cannabis products of high quality to treat specific illnesses. The Company is a medical cannabis finished product producer and therefore has no cultivation operations, it has access to provide a wide variety of different strains, oils, and the latest formulations. The Company intends to provide a range of medical cannabis products which will initially, due to the regulation in Poland, be dried flowers.

At the beginning of 2021, ODI Pharma launched "Project Skin", focusing on the application of CBD in skincare products. The Company's product line will initially consist of a CBD-infused facial cream, facial mask, and body balm, which was produced and launched to the market on the 1<sup>st</sup> of October under the brand "kandol.". kandol. is an innovative brand, focusing on sustainable packaging, based on beauty and scientific knowledge. The products formulations and sustainable approach create a unique market position for ODI Pharma, targeting a small but considerably growing segment of the cannabis industry.

### The products

Medical cannabis comes in a range of different products with different levels of THC (Tetrahydrocannabinol) and CBD (Cannabidiol). The products that ODI Pharma is going to produce for the Polish market, per the *Polish Strategy*, are products that will be approved by the Polish governmental agencies. Initially, the products will be

dried flowers, since this is the product that this far has been regulated in Poland (even though the law in Poland allows for a range of derivatives from the cannabis plant). These products will be based on the raw material of fully approved cannabis imported by the Company and strategic partners. The dried flowers can be consumed by the patients in various ways following the guidelines of the pharmacists. ODI Pharma is evaluating other product types besides dried flowers to be sold on the Polish market.

ODI Pharma intends to be up to date on trends and regulatory requirements and future products may, therefore, differ from the current products. The market demand decides what type of medical cannabis products the Company will supply, which the Company's flexible business model enables. The production of the products is fully integrated with NEUCA. The current market price of dried flowers in Poland is approx. EUR 13.00-16.00 (based on current exchange rate) per gram, ODI Pharma intends to at least match this price, while still providing high-quality products. Whatever product type of medical cannabis ODI Pharma provides, the objective is to be cost-efficient concerning what has previously been stated.

### **Target groups**

There is a total of about 40+ indications in which medical cannabis may potentially show results in terms of efficacy. The Supreme Pharmaceutical Chamber of Poland (Naczelna Izba Aptekarska) estimates an immediate market demand of 300,000 patients by 2025. Jędrzej Sadowski, the author of the bill legalizing cannabis, estimates 300,000 patients as well. ODI Pharma assumes that it will take some years to reach the potential patients' number that uses the product and the Company estimate that this will be reached in 2025. The Polish regulations do not limit the prescriptions for medical cannabis concerning certain ailments – therefore all physicians have the authorization to prescribe medical cannabis to all their patients and all types of illnesses. The Supreme Pharmaceutical Chamber of Poland suggested the application with treatable conditions including nausea caused by chemotherapy, epilepsy, symptoms of multiple sclerosis, and chronic pain.

## ABOUT THE YEAR-END REPORT

### Group structure

ODI Pharma AB was formed on the 23<sup>rd</sup> of October 2019. ODI Pharma AB is the Swedish holding company of ODI Pharma Schweiz AG (100 %). ODI Pharma Schweiz AG has an ownership of 100 % in ODI Pharma Polska Sp. z o.o. The group was established on the 28<sup>th</sup> of June 2018 (the "Group") when ODI Pharma Schweiz AG acquired the shares in ODI Pharma Polska Sp. z o.o.

### Revenue and operating results Q4

The Group's revenue amounted to SEK 50,125 (5,308) in the fourth quarter and resulted in an operating income of SEK -2,372,577 (-1,876,715). A majority of the operating expenses are related to insurance expenses, legal services, procurement of raw materials and products, salaries to salesperson, audit services, and accounting services. The holding company, ODI Pharma AB, has generated revenues of SEK 15,418 (5,307) during the fourth quarter.

### Balance sheet and solidity

ODI Pharma AB was registered with the Swedish Companies Registration Office on the 23<sup>rd</sup> of October 2019 with shareholder equity of SEK 500,000. The Company has no long-term liabilities. The group was established on the 28<sup>th</sup> of June 2018. Total assets of the Group amounted to SEK 10,395,054 (16,880,080) and consisted primarily of cash and cash equivalents. The solidity of the Group was 88,48% (96,55%) at quarter-end. The holding company, ODI Pharma AB, stated total assets of SEK 9,651,264 (16,722,652) consisting primarily of cash and cash equivalents. The solidity of ODI Pharma AB was 90% (97%).

### Cash flow and investments

Cash flow from operations in the Group during the fourth quarter amounted to SEK -2,451,348 (-1,907,140). Cash flow from financing and investment activities during the fourth quarter amounted to SEK 50 (0), resulting in cash flow from April 2022 to June 2022 of SEK -1,672,381 (-1,201,508). The holding company, ODI Pharma AB, showed a cash flow for the period (after financing and investment activity) of SEK -1,496,856 (-1,039,838) during the fourth quarter.

### The share

The shares of ODI Pharma were listed on Spotlight Stock Market on the 23<sup>rd</sup> of January 2020. The short name/ticker is ODI and the ISIN code is SE0013409760. Spotlight Stock Market operates a so-called MTF platform and is a secondary name of ATS Finans AB, a securities company under the supervision of the Swedish Financial Supervisory Authority. ATS Finans AB is a subsidiary of Spotlight Group AB, a company listed on Spotlight Stock Market since the 15<sup>th</sup> of September 2020. On the 30<sup>th</sup> of June 2022, the number of shares in ODI Pharma amounted to 15,220,000 (15,220,000). The average number of shares during the fourth quarter amounted to 15,220,000 (15,220,000). Every share equals the same rights to the Company's assets and results.

### Warrants

No warrants are outstanding to any party.

## Financial calendar

July 2022 – September 2022 (Q1)	24 <sup>th</sup> of November 2022
Annual Report 2021/2022	24 <sup>th</sup> of November 2022
July 2022 – December 2022 (Q2)	23 <sup>rd</sup> of February 2023
July 2022 – March 2023 (Q3)	25 <sup>th</sup> of May 2023
July 2022 – June 2023 (Q4)	24 <sup>th</sup> of August 2023

## Shareholders

The table below presents the current shareholders, as of 30<sup>th</sup> of June 2022, with more than 5 percent of the votes and capital in ODI Pharma AB.

Name	Number of shares	The proportion of votes and capital (%)
Volker Wiederrich	6,255,898	41.10
Derek Simmross	6,250,000	41.06
Niclas Kappelin	1,060,180	6.97
<i>Other shareholders (approx. 1,200)</i>	<i>1,653,922</i>	<i>10.87</i>
<b>Total</b>	<b>15,220,000</b>	<b>100.00</b>

## Auditor's review

The year-end report has not been reviewed by the Company's auditor.

## Accounting policy of the quarterly report

The financial statements of ODI Pharma AB, as well as the ODI Pharma Group, are prepared per the Swedish Annual Accounts Act and the standards of the Swedish Accounting Standards Board (BFNAR) 2012:1 (K3) and Spotlight Stock Market's Rules and Regulations, as applicable. Consolidated accounts include parent company and subsidiaries in which the parent company directly or indirectly owns shares that are more than 50 % of the votes. Intangible and tangible assets are at the acquisition value reduced with accumulated depreciation according to plan and eventually write-downs. Depreciation is done linearly in relation to expected useful life. The financial overviews of ODI Pharma's subsidiaries were prepared in the local currency (CHF for the Swiss subsidiary and PLN for the Polish subsidiary). For this report, the local currencies have been recalculated to SEK in the financial overview, based on data from Sveriges Riksbank on the 30<sup>th</sup> of June 2022, respectively the average exchange rate for the presented time frame.

## Common Control Transaction

During the financial year 2019/2020, ODI Pharma AB acquired ODI Pharma Schweiz AG from the previous owners through a related party transaction. The acquisition was carried out through a promissory note of CHF 100,000, which, in accordance with an established agreement, was subject to set-off in connection with a new issue using the K3 currency conversion principle. K3 does not comment on common control transactions and in the absence of guidance, the company has chosen to report the transaction based on the former group's book values, since the newly formed company is not considered an acquirer in the transaction. This means that ODI

Pharma Sweden AB's consolidated accounts are a continuation of what was previously reported in the ODI Pharma Switzerland Group and the comparative figures presented are the ODI Pharma Switzerland Group's financial information for 2018, adjusted for differences in accounting principles.

### **Operational risks and uncertainties regarding Covid-19**

Like most other companies, ODI Pharma was affected by Covid-19. As announced via a press release, the Board of Directors does not see any impact on the Company's mid-and long-term goals due to Covid-19. At the same time, the current situation has caused ODI to experience a delay in the implementation of the import process. Today, it is not possible to fully review any potential further consequences for the business, and the Company is closely following the development.

### **Other operational risks and uncertainties**

The risks and uncertainties that ODI Pharma's operations are exposed to are summaries related to factors such as development, competition, permissions, capital requirements, customers, suppliers/manufacturers, currencies, and interest rates.

### **Submission of the year-end report**

Stockholm, 25<sup>th</sup> of August 2022

ODI Pharma AB

The Board of Directors

### **For further information, please contact**

Derek Simmross, CEO

E-mail: [info@odipharma.com](mailto:info@odipharma.com)

Website: <https://www.odipharma.com/>

ODI Pharma AB was formed on the 23<sup>rd</sup> of October 2019. ODI Pharma AB is the Swedish holding company of ODI Pharma Schweiz AG and ODI Pharma Polska Sp. z o.o. The group was established on the 28<sup>th</sup> of June 2018.

## INCOME STATEMENT – THE GROUP

SEK	2022-04-01	2021-04-01	2021-07-01	2020-07-01
	2022-06-30	2021-06-30	2022-06-30	2021-06-30
	3 months	3 months	12 months	12 months
<b>Revenue</b>				
Net Sales	14,233	0	544,151	0
Other operating income	35,892	5,308	87,871	23,667
	<b>50,125</b>	<b>5,308</b>	<b>632,022</b>	<b>23,667</b>
<b>Operating expenses</b>				
Cost of goods sold	-164,974	0	-711,451	0
External expenses	-1,540,040	-1,200,865	-5,495,005	-3,248,031
Personal expenses	-699,313	-670,223	-1,625,867	-670,223
Depreciation and amortisation	-1,461	-1,710	-5,588	-6,975
Other operating expenses	-16,915	-9,225	-64,676	-62,686
<b>Operating cost</b>	<b>-2,422,702</b>	<b>-1,882,023</b>	<b>-7,902,586</b>	<b>-3,987,915</b>
<b>Operating income</b>	<b>-2,372,577</b>	<b>-1,876,715</b>	<b>-7,270,564</b>	<b>-3,964,248</b>
<b>Profit/loss from financial items</b>				
Other interest income and similar profit/loss items	-3	-19,641	133	11,490
Interest expense and similar profit/loss items	-5,442	10,198	-28,762	-14,566
<b>Income after financial items</b>	<b>-2,378,022</b>	<b>-1,886,158</b>	<b>-7,299,193</b>	<b>-3,967,324</b>
<b>Income before taxes</b>	<b>-2,378,022</b>	<b>-1,886,158</b>	<b>-7,299,193</b>	<b>-3,967,324</b>
Taxes	-43	1,228	-3,508	-14,372
<b>Net income</b>	<b>-2,378,065</b>	<b>-1,884,930</b>	<b>-7,302,701</b>	<b>-3,981,696</b>
<i>Number of shares in the beginning of the period</i>	15,220,000.00	15,220,000.00	15,220,000.00	15,220,000.00
<i>Number of shares at the end of the period</i>	15,220,000.00	15,220,000.00	15,220,000.00	15,220,000.00
<i>Average number of shares</i>	15,220,000.00	15,220,000.00	15,220,000.00	15,220,000.00
<i>Earnings per share, SEK</i>	-0,16	-0,12	-0,48	-0,26

## BALANCE SHEET – THE GROUP

SEK	2022-06-30	2021-06-30
<b>Assets</b>		
Fixed assets		
<i>Tangible fixed assets</i>		
Equipment, Machines, tools	12,309	11,999
	12,309	11,999
<b>Total fixed assets</b>	<b>12,309</b>	<b>11,999</b>
<b>Current assets</b>		
<b>Inventories</b>		
Raw materials and consumables	348,695	237,066
Finished goods and goods for resale	907,614	0
Advance payments to supplier	188,050	812,469
	<b>1,444,359</b>	<b>1,049,535</b>
<b>Current receivables</b>		
Trade receivables	301,628	0
Tax receivables	228,853	199,864
Other current receivables	757,372	732,572
Prepaid expenses and accrued income	282,744	261,217
	<b>1,570,597</b>	<b>1,193,653</b>
Cash and cash equivalents	7,367,789	14,624,893
<b>Total current assets</b>	<b>10,382,745</b>	<b>16,868,081</b>
<b>TOTAL ASSETS</b>	<b>10,395,054</b>	<b>16,880,080</b>

SEK	2022-06-30	2021-06-30
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Share capital	608,800	608,800
Other contributed capital	22,168,101	21,841,787
Other equity including result for the period	-13,579,253	-6,152,232
<b>Equity attributed to shareholders in parent company</b>	<b>9,197,647</b>	<b>16,298,355</b>
<b>Current liabilities</b>		
Account payables	674,809	149,602
Tax liabilities	0	0
Other current liabilities	7,681	35,493
Accrued expenses and prepaid income	514,917	396,630
<b>Total current liabilities</b>	<b>1,197,407</b>	<b>581,725</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>10,395,054</b>	<b>16,880,080</b>

## CASH FLOW STATEMENT – THE GROUP

SEK	2022-04-01 2022-06-30 3 months	2021-04-01 2021-06-30 3 months	2021-07-01 2022-06-30 12 months	2020-07-01 2021-06-30 12 months
<b>Operating activities</b>				
Net operating profit/loss	-2,372,577	-1,876,715	-7,270,564	-3,964,248
Adjustment for non-cash flow items				
Depreciations and write-downs	1,461	1,710	5,588	6,975
Current exchange differences	-80,232	-32,135	-50,025	34,541
<b>Cash flow from operating activities</b>	<b>-2,451,348</b>	<b>-1,907,140</b>	<b>-7,315,001</b>	<b>-3,922,732</b>
Paid interest	447	-2,460	-234	-5,937
Paid tax	50,584	156,736	32,497	-516,059
<b>Cash flow from operation before change in working capital</b>	<b>-2,400,317</b>	<b>1,752,864</b>	<b>-7,282,738</b>	<b>-4,444,728</b>
Cash flow from change in working capital				
Change in inventories and ongoing works	31,775	-1,049,535	-394,824	-1,049,535
Increase (-) Decrease (+) of operating receivables	54,051	1,086,871	-347,955	-665,603
Increase (+) Decrease (-) of operating liabilities	642,061	514,020	651,175	97,878
<b>Total change in working capital</b>	<b>-1,672,431</b>	<b>-1,201,508</b>	<b>7,374,343</b>	<b>-6,061,988</b>
<b>Investment activities</b>				
Investments in tangible fixed assets	50	0	4,109	0
<b>Cash flow from investment activities</b>	<b>50</b>	<b>0</b>	<b>4,109</b>	<b>0</b>
<b>Financing activities</b>				
New share issue	0	0	0	0
New share issue expenses	0	0	0	258,502
<b>Cash flow from financing activities</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>258,502</b>
<b>Cash flow for the period</b>	<b>-1,672,381</b>	<b>-1,201,508</b>	<b>7,370,234</b>	<b>-5,803,486</b>
Cash and cash equivalents at beginning of year	8,985,958	15,790,836	14,624,893	20,513,417
Effects of exchange rate changes on cash	54,212	35,565	113,130	-85,038
<b>Cash and cash equivalents at end of year</b>	<b>7,367,789</b>	<b>14,624,893</b>	<b>7,367,789</b>	<b>14,624,893</b>

## INCOME STATEMENT – ODI PHARMA AB

SEK	2022-04-01	2021-04-01	2021-07-01	2020-07-01
	2022-06-30	2021-06-30	2022-06-30	2021-06-30
	3 months	3 months	12 months	12 months
<b>Revenue</b>				
Net sales	0	0	527,200	0
Other operating income	15,418	5,307	46,161	23,667
	<b>15,418</b>	<b>5,307</b>	<b>573,361</b>	<b>23,667</b>
<b>Operating expenses</b>				
Cost of goods sold	-166,280	0	-635,954	0
External expenses	-1,477,719	-1,237,703	-5,822,289	-3,249,731
Personal expenses	-698,887	670,223	-1,591,647	-670,223
Other operating expenses	-14,031	-1,885	-59,750	-22,999
<b>Total operating cost</b>	<b>-2,356,917</b>	<b>-1,909,811</b>	<b>-8,109,640</b>	<b>-3,942,953</b>
<b>Operating income</b>	<b>-2,341,499</b>	<b>-1,904,504</b>	<b>-7,536,279</b>	<b>-3,919,286</b>
<b>Income from financial items</b>				
Other interest income and similar profit/loss items	0	0	0	0
Interest expense and similar profit/loss items	-858	-4,805	-6,825	-5,014
<b>Income after financial items</b>	<b>-2,342,357</b>	<b>-1,909,309</b>	<b>-7,543,104</b>	<b>-3,924,300</b>
<b>Income before taxes</b>	<b>-2,342,357</b>	<b>-1,909,309</b>	<b>-7,543,104</b>	<b>-3,924,300</b>
Taxes	0	0	0	0
<b>Net income</b>	<b>-2,342,357</b>	<b>-1,909,309</b>	<b>-7,543,104</b>	<b>-3,924,300</b>
<i>Number of shares in the beginning of the period</i>	15,220,000.00	15,220,000.00	15,220,000.00	15,220,000.00
<i>Number of shares at the end of the period</i>	15,220,000.00	15,220,000.00	15,220,000.00	15,220,000.00
<i>Average number of shares</i>	15,220,000.00	15,220,000.00	15,220,000.00	15,220,000.00
<i>Earnings per share, SEK</i>	-0,15	-0,13	-0,50	-0,26

## BALANCE SHEET – ODI PHARMA AB

SEK	2022-06-30	2021-06-30
<b>ASSETS</b>		
<b>Fixed assets</b>		
<i>Financial fixed assets</i>		
Shares in group companies	967,200	967,200
	<b>967,200</b>	<b>967,200</b>
<b>Total fixed assets</b>	<b>967,200</b>	<b>967,200</b>
<b>Current assets</b>		
<b>Inventories</b>		
Raw materials and consumables	348,695	237,066
Finished goods and goods for resale	907,614	0
Advance payments to suppliers	188,050	812,469
	<b>1,444,359</b>	<b>1,049,535</b>
<b>Current receivables</b>		
Trade receivables	237,709	0
Other current receivables	633,330	499,267
Prepaid expenses and accrued income	436,063	421,379
	<b>1,307,102</b>	<b>920,646</b>
Cash and cash equivalents	5,932,603	13,785,271
<b>Total current assets</b>	<b>8,684,064</b>	<b>15,755,452</b>
<b>TOTAL ASSETS</b>	<b>9,651,264</b>	<b>16,722,652</b>

SEK

2022-06-30

2021-06-30

## EQUITY AND LIABILITIES

## Equity

*Restricted reserves*

Share capital	608,800	608,800
---------------	---------	---------

*Non-restricted reserves*

Share premium reserve	21,472,267	21,472,267
-----------------------	------------	------------

Retained earnings	-5,899,171	-1,974,870
-------------------	------------	------------

Profit or loss for the period	-7,543,104	-3,924,300
-------------------------------	------------	------------

---

<b>Total equity</b>	<b>8,638,792</b>	<b>16,181,897</b>
---------------------	------------------	-------------------

## Current liabilities

Account payables	475,359	67,542
------------------	---------	--------

Liabilities to group companies	76,194	104,898
--------------------------------	--------	---------

Other current liabilities	7,681	35,493
---------------------------	-------	--------

Accrued expenses and prepaid income	453,238	332,822
-------------------------------------	---------	---------

---

<b>Total current liabilities</b>	<b>1,012,472</b>	<b>540,755</b>
----------------------------------	------------------	----------------

---

<b>TOTAL EQUITY AND LIABILITIES</b>	<b>9,651,264</b>	<b>16,722,652</b>
-------------------------------------	------------------	-------------------

---

## CASH FLOW STATEMENT – ODI PHARMA AB

SEK	2022-04-01 2022-06-30 3 months	2021-04-01 2021-06-30 3 months	2021-07-01 2022-06-30 12 months	2020-07-01 2021-06-30 12 months
<b>Operating activities</b>				
Net operating profit/loss	-2,295,700	-1,904,504	-7,536,279	-3,919,286
Adjustment for non-cash flow items				
Depreciations and write-downs	0	0	0	0
Current exchange differences	0	0	0	0
Other items not affecting cash flow	-2	0	-2	0
<b>Cash flow from operating activities</b>	<b>-2,295,702</b>	<b>-1,904,504</b>	<b>-7,536,281</b>	<b>-3,919,286</b>
Paid interest	0	-262	-123	-471
Paid tax	0	0	0	0
<b>Cash flow before change in working capital</b>	<b>-2,295,702</b>	<b>-1,904,766</b>	<b>-7,536,404</b>	<b>-3,919,757</b>
<i>Cash flow from change in working capital</i>				
Change in inventories and ongoing works	31,775	-1,049,534	-394,824	-1,049,534
Increase (-) Decrease (+) of operating receivables	337,679	1,493,470	-386,456	-770,294
Increase (+) Decrease (-) of operating liabilities	429,392	420,992	471,718	299,406
<b>Total change in working capital</b>	<b>-1,496,856</b>	<b>-1,039,838</b>	<b>-7,845,966</b>	<b>-5,440,179</b>
<i>Financing activities</i>				
New shares issue	0	0	0	0
New share issue expenses	0	0	0	258,502
<b>Cash from financing activities</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>258,502</b>
<b>Cash flow for the period</b>	<b>-1,496,856</b>	<b>1,039,838</b>	<b>-7,845,966</b>	<b>-5,181,677</b>
Cash and cash equivalents at the beginning of year	7,430,317	14,829,653	13,785,271	18,971,492
Effects of exchange rate changes on cash	-853	-4,544	-6,702	-4,544
<b>Cash and cash equivalents at the end of year</b>	<b>5,932,603</b>	<b>13,785,271</b>	<b>5,932,603</b>	<b>13,785,271</b>



**ODI Pharma**

[www.odipharma.com](http://www.odipharma.com)